Navigation Links
Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
Date:10/26/2009

BETHESDA, Md., Oct. 26 /PRNewswire-FirstCall/ -- Hanger Orthopedic Group, Inc. (NYSE: HGR) announced net sales of $192.3 million for the quarter ended September 30, 2009, an increase of $13.6 million, or 7.6%, from $178.7 million in the prior year. Earnings per share for the third quarter of 2009 were $0.30 per diluted share compared to $0.23 per diluted share for the same period in 2008.

The $13.6 million, or 7.6%, sales increase for the quarter ended September 30, 2009 was primarily the result of a $6.7 million, or 4.3%, increase in same-center sales in our patient care centers, a $2.1 million, or 10.0%, increase in sales of the Company's distribution segment and a $4.8 million increase principally related to sales from acquired entities. The combination of increased sales and effective expense management resulted in income from operations increasing $3.5 million, or 17.4%, to $23.8 million for the third quarter of 2009, compared to last year.

Net income increased $2.3 million, or 31.4%, to $9.6 million in the third quarter of 2009 from $7.3 million last year. In addition to improved income from operations, net income benefited from lower variable interest cost in the third quarter of 2009.

Net sales for the nine months ended September 30, 2009 increased by $37.4 million, or 7.2%, to $555.0 million from $517.6 million last year. The sales increase was principally the result of a $19.2 million, or 4.3%, increase in same-center sales in our patient care centers, a $5.0 million, or 8.1%, increase in sales of the Company's distribution segment and a $13.2 million increase principally related to sales from acquired entities.

As was the case for the quarter, the growth in sales and expense management helped increase income from operations by $7.2 million, or 12.9%, to $63.0 million for the nine months ended September 30, 2009 compared to the same period last year. Operating income as a percentage of sales increased to 11.4% for the nine months ended September 30, 2009 compared to 10.8% in the same period of 2008.

Net income applicable to common stock for the nine months ended September 30, 2009 increased by 27.9% to $24.2 million, or $0.76 per diluted share, compared to pro forma net income applicable to common stock of $18.9 million, or $0.60 per diluted share, in the prior year. In addition to improved income from operations, net income benefited from lower variable interest costs during 2009. The pro forma results for the nine months ended September 30, 2008 assume that the one-time, in-kind preferred stock dividend described below occurred and the preferred stock was converted to common stock at the beginning of the period. Net income applicable to common stock for the nine months ended September 30, 2008 on a GAAP basis was $13.2 million, or $0.52 per diluted share.

Cash from operations for the three months ended September 30, 2009 was $25.4 million, a $3.1 million, or 13.9% increase, compared to 2008. The improvement was primarily the result of improved operating results and a $0.8 million decrease in working capital. Days sales outstanding were reduced by 3 days to a record low of 47 days as of September 30, 2009 from 50 days as of September 30, 2008.

As of September 30, 2009, $76.1 million, or 18.6%, of the Company's total debt of $409.7 million was subject to variable interest rates. The Company had total liquidity of $131.2 million, comprised of $78.4 million of cash and $52.8 million available under its revolving credit facility at September 30, 2009. On October 23, 2009, Barclays Bank replaced $10.0 million of the $17.8 million defaulted Lehman commitment under the revolving credit facility, which increases the current amount available under the credit facility to $62.8 million. The Company believes that it has sufficient liquidity to conduct its normal operations and fund its acquisition plans in 2009.

The Company is reaffirming its full year 2009 sales guidance of $750 to $760 million and increasing its 2009 diluted EPS guidance of $1.02 to $1.04 to $1.05 to $1.07.

"We are very pleased with our third quarter results, as they exceeded our expectations, represented solid operational execution and generated strong cash flow," commented Thomas F. Kirk, President and Chief Executive Officer of Hanger Orthopedic Group. Mr. Kirk added, "Patient care centers revenues grew at 6.6% and our efforts on expense management continue to be reflected in our results. Since the third quarter of last year, we have improved operating margins for the quarter by 100 basis points to 12.4%. We are also extremely pleased with the added commitment to our revolver and liquidity, because it reflects the confidence our lenders have in our consistent execution. I am proud of our teams' efforts in this economic environment and we are actively monitoring the proposed health care reforms and how they could impact our future prospects."

In June 2008, the Company's common stock performance triggered an acceleration of preferred stock dividends as a result of the Company's average closing price of its common stock price exceeding the Company's forced conversion price of the Series A Convertible Preferred Stock by 200% for a 20-trading day period. This event accelerated the payment of these dividends due from the time of the event through May 26, 2011. The accelerated dividends were paid in the form of increased stated value of preferred stock, in lieu of cash. As a result, the Company recorded an in-kind dividend on its preferred stock of $5.3 million in the quarter ended June 30, 2008, which represented 0.7 million additional common shares on an as-converted basis.

Hanger Orthopedic Group, Inc., headquartered in Bethesda, Maryland, is the world's premier provider of orthotic and prosthetic patient care services. Hanger is the market leader in the United States, owning and operating 669 patient care centers in 45 states and the District of Columbia, with over 3,700 employees including 1,095 practitioners (as of September 30, 2009). Hanger is organized into four units. The two key operating units are patient care, which consists of nationwide orthotic and prosthetic practice centers, and distribution, which consists of distribution centers managing the supply chain of orthotic and prosthetic componentry to Hanger and third party patient care centers. The third is Linkia, which is the first and only provider network management company for the orthotics and prosthetics industry. The fourth unit, Innovative Neurotronics, introduces emerging neuromuscular technologies developed through independent research in a collaborative effort with industry suppliers worldwide. For more information on Innovative Neurotronics, Inc. or the WalkAide®, visit http://www.ininc.us. For more information on Hanger, visit http://www.hanger.com.

This document contains forward-looking statements relating to the Company's results of operations. The United States Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. Statements relating to future results of operations in this document reflect the current views of management. However, various risks, uncertainties and contingencies could cause actual results or performance to differ materially from those expressed in, or implied by, these statements, including the Company's ability to enter into and derive benefits from managed care contracts, the demand for the Company's orthotic and prosthetic services and products and the other factors identified in the Company's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934. The Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

-tables to follow-


                           Hanger Orthopedic Group, Inc.
            (Dollars in thousands, except share and per share amounts)
                                    (Unaudited)

                                Three Months Ended       Nine Months Ended
                                   September 30,           September 30,
    Income Statement:            2009        2008        2009        2008
    -----------------            ----        ----        ----        ----
    Net sales                 $192,296    $178,742    $554,966    $517,582
    Cost of goods
     sold - materials           58,887      53,411     168,784     155,409
    Personnel costs             66,976      63,712     196,783     185,595
    Other operating
     expenses                   38,669      37,047     114,085     107,950
    Depreciation and
     amortization                4,002       4,334      12,265      12,805
                                 -----       -----      ------      ------
    Income from
     operations                 23,762      20,238      63,049      55,823
    Interest expense             7,692       8,005      22,894      24,308
    Unrealized gain from
     interest rate swap              -           -         167           -
                                    --          --         ---          --
    Income before taxes         16,070      12,233      40,322      31,515
    Provision for
     income taxes                6,428       4,893      16,129      12,606
                                 -----       -----      ------      ------
    Net income                   9,642       7,340      24,193      18,909
       Less preferred
        stock dividend -
        Series A
        Convertible
        Preferred Stock              -           -           -       5,670
                                    --          --          --       -----
    Net income applicable
     to common stock            $9,642      $7,340     $24,193     $13,239
                                ======      ======     =======     =======

    Basic Per Common
     Share Data:
    ----------------
    Net income                   $0.31       $0.27       $0.77       $0.54
                                 =====       =====       =====       =====
    Shares used to
     compute
     basic per common
     share amounts          31,578,889  27,004,581  31,263,458  24,300,945
                            ==========  ==========  ==========  ==========

    Diluted Per Common
     Share Data:
    ------------------
    Net income                   $0.30       $0.23       $0.76       $0.52
                                 =====       =====       =====       =====
    Shares used to
     compute
     diluted per common
     share amounts          32,214,321  31,990,924  31,938,613  25,399,721
                            ==========  ==========  ==========  ==========


                                                                  Nine Months
                                                                     Ended
                                                                   September
    Pro-forma:                                                     30, 2008
    ----------
    Net income applicable
     to common stock                                                13,239
    Preferred stock dividend -
     Series A Convertible
     Preferred Stock                                                 5,670
                                                                     -----
    Pro-forma net income
     applicable to
     common stock                                                  $18,909
                                                                   =======

    Diluted Per Share Data:
    -----------------------
    Pro-forma net income
     per diluted common share                                        $0.60
                                                                     =====

    Shares used to compute
     diluted per common
     share amounts                                              25,399,721
    Effects of conversion
     of convertible
     preferred stock (1)                                         6,090,608
                                                                 ---------
    Shares used to compute
     diluted per common
     share amounts,
     Pro-forma basis                                            31,490,329
                                                                ==========


    (1) Assumes Preferred Stock dividend acceleration event occurred
        January 1, 2008.  The Company believes the presentation of the
        pro-forma results, adjusted for the effects of the acceleration of
        the Preferred Stock dividend at the beginning of the period, is
        more reflective of the Company's current diluted operating results
        and provides investors with additional useful information to
        measure the Company's on-going performance.


                                 Three Months Ended       Nine Months Ended
                                    September 30,           September 30,
    Income Statement as
     a % of Net Sales:            2009        2008        2009        2008
    -------------------           ----        ----        ----        ----
    Net sales                    100.0%      100.0%      100.0%      100.0%
    Cost of goods
     sold - materials             30.6%       29.9%       30.4%       30.0%
    Personnel costs               34.8%       35.6%       35.4%       35.9%
    Other operating
     expenses                     20.1%       20.7%       20.6%       20.8%
    Depreciation
     and amortization              2.1%        2.4%        2.2%        2.5%
                                   ---         ---         ---         ---
    Income from
     operations                   12.4%       11.4%       11.4%       10.8%
    Interest expense               4.0%        4.5%        4.1%        4.7%
    Unrealized gain from
     interest rate swap            0.0%        0.0%        0.0%        0.0%
                                   ---         ---         ---         ---
    Income before taxes            8.4%        6.9%        7.3%        6.1%
    Provision for
     income taxes                  3.3%        2.8%        2.9%        2.4%
                                   ---         ---         ---         ---
    Net income                     5.1%        4.1%        4.4%        3.7%
                                   ===         ===         ===         ===



                          Hanger Orthopedic Group, Inc.
                                   (Unaudited)

                                   Three Months Ended  Nine Months Ended
                                      September 30,        September 30,
    Cash Flow Data:                 2009        2008     2009     2008
    ---------------                 ----        ----     ----     ----
    Cash flow from operations     $25,388     $22,285  $46,149  $34,855
    Capital expenditures           $6,577      $4,172  $12,675  $12,012
    Increase (decrease)
     in cash                       $2,005     $29,571  $19,969  $26,587

    Balance Sheet Data:      Sept. 30, 2009 Dec. 31, 2008
    -------------            -------------- -------------
    Cash and cash equivalents     $78,382     $58,413
    Days Sales Outstanding
     (DSO's)                           47          51
    Working Capital              $219,025    $200,248
    Total Debt                   $409,714    $422,324
    Shareholders' Equity         $301,264    $266,866

                                   Three Months Ended  Nine Months Ended
    Percentage of                     September 30,        September 30,
     net sales from:                2009        2008     2009     2008
                                    ----        ----     ----     ----
      Patient-care
       services                      87.9%       88.0%    87.9%    87.8%
      Distribution                   12.0%       11.7%    11.9%    11.8%

    Payor mix:
      Commercial and other           59.5%       59.4%    59.0%    60.0%
      Medicare                       29.1%       28.8%    29.5%    28.4%
      Medicaid                        6.1%        6.3%     6.2%     6.2%
      VA                              5.3%        5.5%     5.3%     5.4%

    Statistical Data:                                   Nine Months Ended
    -----------------                                      September 30,
                                                         2009     2008
                                                         ----     ----
    Patient-care centers                                   669      668
    Number of practitioners                              1,095    1,080
    Number of states
     (including D.C.)                                       46       46

SOURCE Hanger Orthopedic Group, Inc.


'/>"/>
SOURCE Hanger Orthopedic Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Solar power game-changer: Near perfect absorption of sunlight, from all angles
2. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
3. Northeast Indiana Regional Partnership to Participate in 2009 Orthopedic Design & Technology Conference & Exhibition
4. Lilly Endowment Awards $7 Million Grant to Establish Orthopedics and Community Initiative in Kosciusko County, IN
5. Warsaw, Ind. Orthopedics Industry and Community Leaders to Make Major Announcement
6. Robert Zanotti, MD, Is First Lorain County, Ohio Orthopedic Surgeon to Perform Reverse Total Shoulder Replacement
7. William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement
8. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
9. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
10. George Washington University Hospital Purchases Orthocrats TraumaCad(TM) for Orthopedic Preoperative Planning
11. South Palm Orthospine Institute Now Open: World Renowned Orthopedic Specialist and Author, Stewart G. Eidelson, Announced the New Practice with a Focus on Spine and Spinal Stenosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 08, 2016 , ... Net-Translators, ... today the launch of its revamped and improved website. In an on-going effort ... the redesigned website will better communicate how the company designs and delivers thorough, ...
(Date:2/9/2016)... ... February 09, 2016 , ... The American Academy ... history, it is offering its 2016 AAT Member Certification Qualification Course for Technicians via ... for the webinar, which will include a detailed review of hardware, software, and camera ...
(Date:2/9/2016)...  DNAtrix, a clinical stage, biotechnology company ... its lead product, DNX-2401, has been designated ... medicinal product for the treatment of glioma. ... approximately 25,000 people a year in the ... --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists ... Camp Experiences SHPG ... lives of children born with rare diseases, as well as the ... announcing a new initiative designed to positively affect the lives of ... rare disease care. --> To mark the company,s founding ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
Breaking Biology News(10 mins):